Literature DB >> 30352774

Extreme hypertriglyceridemia: Genetic diversity, pancreatitis, pregnancy, and prevalence.

Vadzim Chyzhyk1, Sarah Kozmic2, Alan S Brown1, Lisa C Hudgins3, Thomas J Starc4, Ashley Deleigh Davila5, Thomas C Blevins5, Margaret R Diffenderfer6, Lihong He6, Andrew S Geller6, Caitlin Rush6, Robert A Hegele7, Ernst J Schaefer8.   

Abstract

BACKGROUND: Triglyceride (TG) concentrations >2000 mg/dL are extremely elevated and increase the risk of pancreatitis.
OBJECTIVES: We characterized five cases and two kindreds and ascertained prevalence in a reference laboratory population.
METHODS: Plasma lipids and DNA sequences of LPL, GPIHBP1, APOA5, APOC2, and LMF1 were determined in cases and two kindreds. Hypertriglyceridemia prevalence was assessed in 440,240 subjects.
RESULTS: Case 1 (female, age 28 years) had TG concentrations >2000 mg/dL and pancreatitis since infancy. She responded to diet and medium-chain triglycerides, but not medications. During two pregnancies, she required plasma exchange for TG control. She was a compound heterozygote for a p.G236Gfs*15 deletion and a p.G215E missense mutation at LPL, as was one sister with hypertriglyceridemia and pancreatitis during pregnancy. Her father was heterozygous for the deletion and had hypertriglyceridemia and recurrent pancreatitis. Other family members had either the missense mutation or the deletion, and had hypertriglyceridemia but no pancreatitis. In kindred 2, three preschool children had severe hypertriglyceridemia and were homozygous for a GPIHBP1 p.T108R missense mutation. Case 5 (male, age 43 years) presented with pancreatitis and TG levels >5000 mg/dL and had heterozygous GPIHBP1 p.G175R and APOC2 intron 2-4G>C mutations. On diet, fenofibrate, fish oil, and atorvastatin, his TG concentration was 2526 mg/dL, but normalized to <100 mg/dL with added pioglitazone. In our population study, 60 subjects (0.014%) of 440,240 had TG concentrations >2000 mg/dL, and 66.7% were diabetic and had elevated insulin levels.
CONCLUSIONS: Extreme hypertriglyceridemia is rare (0.014%); and during pregnancy, it may require plasma exchange.
Copyright © 2018 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chylomicronemia; Genetics; Pancreatitis; Plasmapheresis; Population prevalence; Pregnancy; Triglycerides

Mesh:

Substances:

Year:  2018        PMID: 30352774     DOI: 10.1016/j.jacl.2018.09.007

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  16 in total

Review 1.  Chylomicronemia from GPIHBP1 autoantibodies.

Authors:  Kazuya Miyashita; Jens Lutz; Lisa C Hudgins; Dana Toib; Ambika P Ashraf; Wenxin Song; Masami Murakami; Katsuyuki Nakajima; Michael Ploug; Loren G Fong; Stephen G Young; Anne P Beigneux
Journal:  J Lipid Res       Date:  2020-09-18       Impact factor: 5.922

Review 2.  GPIHBP1 and Lipoprotein Lipase, Partners in Plasma Triglyceride Metabolism.

Authors:  Stephen G Young; Loren G Fong; Anne P Beigneux; Christopher M Allan; Cuiwen He; Haibo Jiang; Katsuyuki Nakajima; Muthuraman Meiyappan; Gabriel Birrane; Michael Ploug
Journal:  Cell Metab       Date:  2019-07-02       Impact factor: 27.287

3.  A Modern Approach to Dyslipidemia.

Authors:  Amanda J Berberich; Robert A Hegele
Journal:  Endocr Rev       Date:  2022-07-13       Impact factor: 25.261

Review 4.  Clinical review on triglycerides.

Authors:  Ulrich Laufs; Klaus G Parhofer; Henry N Ginsberg; Robert A Hegele
Journal:  Eur Heart J       Date:  2020-01-01       Impact factor: 29.983

5.  Therapeutic plasma exchange for the management of severe gestational hypertriglyceridaemic pancreatitis due to lipoprotein lipase mutation.

Authors:  Albert S Kim; Rashida Hakeem; Azaliya Abdullah; Amanda J Hooper; Michel C Tchan; Thushari I Alahakoon; Christian M Girgis
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-03-13

6.  Maternally inherited diabetes and deafness coexists with lipoprotein lipase gene mutation-associated severe hyperlipidemia that was resistant to fenofibrate and atorvastatin, but sensitive to bezafibrate: A case report.

Authors:  Xiaojuan Zhang; Yongyong Chen; Nanwei Tong; Qing Shao; Yueyang Zhou; Tong Mu; Xiaoling Yang; Yuwei Zhang
Journal:  J Diabetes Investig       Date:  2021-09-22       Impact factor: 4.232

Review 7.  The Genetic Basis of Hypertriglyceridemia.

Authors:  Germán D Carrasquilla; Malene Revsbech Christiansen; Tuomas O Kilpeläinen
Journal:  Curr Atheroscler Rep       Date:  2021-06-19       Impact factor: 5.113

Review 8.  Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.

Authors:  Oluwayemisi Esan; Anthony S Wierzbicki
Journal:  Drug Des Devel Ther       Date:  2020-07-06       Impact factor: 4.162

9.  Six years' experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias.

Authors:  Jacqueline S Dron; Jian Wang; Adam D McIntyre; Michael A Iacocca; John F Robinson; Matthew R Ban; Henian Cao; Robert A Hegele
Journal:  BMC Med Genomics       Date:  2020-02-10       Impact factor: 3.063

Review 10.  A Comprehensive Update on the Chylomicronemia Syndrome.

Authors:  Ronald B Goldberg; Alan Chait
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-23       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.